- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07580248
Effects of Supplementation on Performance in Football Players (FOOTBALL-TCP)
Effects of Combined Taurine, Caffeine, and Phosphatidylserine Supplementation on Physical and Cognitive Performance in Professional Male Football Players
This study investigated the effects of short-term supplementation with taurine, caffeine, and phosphatidylserine on physical and cognitive performance in professional male football players. Eighty-one players were randomly assigned to one of three groups: placebo, taurine plus caffeine, or taurine plus caffeine combined with phosphatidylserine. Supplementation was administered for 10 days, with a final dose taken 60 minutes before a standardized 105-minute football training session.
Primary and secondary outcomes included sprint performance, reaction time, GPS-derived locomotor variables, and technical and tactical performance indicators. The aim of the study was to evaluate whether combined multi-ingredient supplementation could improve performance and attenuate fatigue-related declines under match-like conditions.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
This randomized, placebo-controlled, single-blind study evaluated the effects of combined supplementation with taurine, caffeine, and phosphatidylserine on physical and cognitive performance in professional male football players.
Eighty-one participants aged 19-32 years were randomly assigned to one of three groups: placebo (lactose), taurine plus caffeine (1500 mg taurine + 200 mg caffeine), or taurine plus caffeine plus phosphatidylserine (1500 mg taurine + 150 mg caffeine + 300 mg phosphatidylserine daily for 10 days). All participants completed a 10-day supplementation period, followed by a standardized 105-minute football training session.
Outcome measures included sprint performance (30 m sprint time), reaction time (visual and auditory), GPS-derived variables (total distance, sprint activity, speed, accelerations, and decelerations), and technical and tactical performance indicators assessed by coaching staff and video analysis.
The study was conducted under controlled environmental conditions and in accordance with standardized training procedures. Data were analyzed using analysis of variance (ANOVA) with post hoc testing. The aim was to determine whether multi-ingredient supplementation could enhance performance and reduce fatigue-related declines in a football-specific setting.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Łódżkie
-
Lodz, Łódżkie, Polen, 94-020
- ŁKS Łódź
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Male professional football (soccer) players
- Age 19-32 years
- Currently participating in regular team training (4-5 sessions per week)
- Medically cleared for participation in high-intensity physical activity
- Provided written informed consent
Exclusion Criteria:
- Current injury or musculoskeletal condition affecting performance
- Chronic disease or medical condition
- Use of medications that may affect physical or cognitive performance
- Regular use of dietary supplements or caffeine prior to the study period
- Smoking or alcohol consumption
- Failure to comply with study procedures
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
Participants received a placebo (lactose) daily for 10 days.
|
Placebo (lactose) administered daily for 10 days
|
|
Experimental: Taurine + Caffeine
Participants received taurine (1500 mg) and caffeine (200 mg) daily for 10 days.
|
Taurine 1500 mg and caffeine 200 mg administered daily for 10 days
|
|
Experimental: Taurine + Caffeine + PS
Participants received taurine (1500 mg), caffeine (150 mg), and phosphatidylserine (300 mg) daily for 10 days.
|
Taurine 1500 mg, caffeine 150 mg, and phosphatidylserine 300 mg administered daily for 10 days
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
30 m sprint time (seconds)
Zeitfenster: Day 10 (final training session following supplementation)
|
Time to complete a 30 meter sprint under standardized conditions, expressed in seconds; calculated as the mean of valid trials.
|
Day 10 (final training session following supplementation)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Reaction time (visual and auditory)
Zeitfenster: Day 10 (post-supplementation)
|
Visual and auditory reaction time measured using standardized computerized reaction time tests (e.g., validated software-based assessment tools), expressed as mean response time in seconds across valid trials.
|
Day 10 (post-supplementation)
|
|
Total distance (meters)
Zeitfenster: Day 10 (during standardized training session)
|
Total distance covered during the standardized training session, measured using GPS tracking devices (e.g., 10 Hz GPS units), expressed in meters.
|
Day 10 (during standardized training session)
|
|
Running speed (m/s)
Zeitfenster: Day 10 (during standardized training session)
|
Mean running speed during the standardized training session, measured using GPS tracking devices (e.g., 10 Hz GPS units), expressed in meters per second.
|
Day 10 (during standardized training session)
|
|
Sprint count (number)
Zeitfenster: Day 10 (during standardized training session)
|
Total number of sprint efforts recorded during the standardized training session using GPS tracking devices.
|
Day 10 (during standardized training session)
|
|
High-speed running distance (meters)
Zeitfenster: Day 10 (during standardized training session)
|
Distance covered at high-speed running thresholds during the standardized training session, measured using GPS tracking and expressed in meters.
|
Day 10 (during standardized training session)
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Sprint time decline (%)
Zeitfenster: Day 10 (during final training session; comparison between first and second halves)
|
Percentage decline in 30 m sprint time between the first and second halves of the standardized training session, measured using electronic timing gates and expressed as percentage change.
|
Day 10 (during final training session; comparison between first and second halves)
|
|
Running speed decline (%)
Zeitfenster: Day 10 (during final training session; comparison between first and second halves)
|
Percentage decline in running speed between the first and second halves of the standardized training session, measured using GPS tracking devices and expressed as percentage change.
|
Day 10 (during final training session; comparison between first and second halves)
|
|
Passing accuracy (%)
Zeitfenster: Day 10 (during standardized training session)
|
Percentage of successful passes during the standardized training session, assessed using video-based performance analysis and expressed as a percentage.
|
Day 10 (during standardized training session)
|
|
Dribbling success (%)
Zeitfenster: Day 10 (during standardized training session)
|
Percentage of successful dribbling attempts during the standardized training session, assessed using video-based performance analysis and expressed as a percentage.
|
Day 10 (during standardized training session)
|
|
Ball recoveries (number)
Zeitfenster: Day 10 (during standardized training session)
|
Total number of ball recoveries performed during the standardized training session, assessed using video-based performance analysis and expressed as a count.
|
Day 10 (during standardized training session)
|
|
Tactical performance score (units)
Zeitfenster: Day 10 (during standardized training session)
|
Coach-rated tactical performance during the standardized training session, including positioning, decision-making, and support play, assessed using a standardized rating scale and expressed in standardized score units.
|
Day 10 (during standardized training session)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Krzysztof Maciej MIZERA, PhD, 1. Vizja University in Warsaw, Faculty of Medical Sciences and Health Sciences, 01-143 Warsaw, Poland
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Schwefelverbindungen
- Organische Chemikalien
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Lipide
- Kohlenwasserstoffe, acyclisch
- Kohlenwasserstoffe
- Alkaloide
- Purinonen
- Purines
- Alkane
- Alkanesulfonsäuren
- Sulfonsäuren
- Schwefelsäuren
- Membranlipide
- Xanthine
- Glycerophospholipide
- Phosphatidsäuren
- Glycerophosphate
- Phospholipide
- Koffein
- Taurin
- Phosphatidylserine
Andere Studien-ID-Nummern
- MIZERA-2025-FOOTBALL-RCT
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Placebo
-
SamA Pharmaceutical Co., LtdUnbekanntAkute Bronchitis | Akute Infektion der oberen AtemwegeKorea, Republik von
-
National Institute on Drug Abuse (NIDA)AbgeschlossenCannabiskonsumVereinigte Staaten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAbgeschlossenMännliche Probanden mit Typ-II-Diabetes (T2DM)Deutschland
-
Texas A&M UniversityNutraboltAbgeschlossenGlukose- und Insulinreaktion
-
LifeMine TherapeuticsRekrutierung
-
Longeveron Inc.BeendetHypoplastisches LinksherzsyndromVereinigte Staaten
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Abgeschlossen
-
JW PharmaceuticalRekrutierungUterusmyome | MenorrhagieSüdkorea
-
Soroka University Medical CenterAbgeschlossen